<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="amount and lower levels of albumin while the levels of" exact="creatine" post="kinase, aminotransferases, lactic dehydrogenases, and C-protein increased [21]. Patients"/>
 <result pre="of internalization including that of SARS-CoV. Therefore, drugs such as" exact="chlorpromazine" post="inhibiting clathrin-mediated endocytosis are tested for their potential in"/>
 <result pre="Potential candidates for repurposing for SARS-CoV-2 5.1.1 Antimalarial agents 5.1.1.1" exact="Chloroquine" post="The SARS-CoV-2 (COVID-19) host interactions can be modulated by"/>
 <result pre="be modulated by small-molecule agents authorized for other human diseases." exact="Chloroquine" post="(CQ), a commonly used anti-malarial drug and authorized immune"/>
 <result pre="in China for the safety and efficacy of CQ and" exact="hydroxychloroquine" post="for treating COVID-19 linked pneumonia [66]. Reports have so"/>
 <result pre="COVID-19 linked pneumonia [66]. Reports have so far shown that" exact="chloroquine" post="phosphate is preferred in managing the treatment by constraining"/>
 <result pre="years, making it potential and clinically beneficial towards COVID-19. 5.1.1.2" exact="Hydroxychloroquine" post="Hydroxychloroquine (HCQ), which demonstrates a highly related structure (as"/>
 <result pre="making it potential and clinically beneficial towards COVID-19. 5.1.1.2 Hydroxychloroquine" exact="Hydroxychloroquine" post="(HCQ), which demonstrates a highly related structure (as shown"/>
 <result pre="from their chart defined protocol, and 6 patients obtained simultaneous" exact="azithromycin" post="(AZM) treatment to avoid bacterial superinfection. Patients who received"/>
 <result pre="a larger sample size. Fig. 4 The chemical composition of" exact="chloroquine" post="and hydroxychloroquine. Fig. 5 Schematic representation of chloroquine and"/>
 <result pre="composition of chloroquine and hydroxychloroquine. Fig. 5 Schematic representation of" exact="chloroquine" post="and hydroxychloroquine antiviral mechanisms. 5.1.2 Antiviral agents 5.1.2.1 Lopinavir"/>
 <result pre="chloroquine and hydroxychloroquine. Fig. 5 Schematic representation of chloroquine and" exact="hydroxychloroquine" post="antiviral mechanisms. 5.1.2 Antiviral agents 5.1.2.1 Lopinavir and ritonavir"/>
 <result pre="and hydroxychloroquine antiviral mechanisms. 5.1.2 Antiviral agents 5.1.2.1 Lopinavir and" exact="ritonavir" post="Several kinds of research have concentrated on repurposing existing"/>
 <result pre="confirmed to be effective towards SARS-CoV and MERS-CoV such as" exact="lopinavir" post="(LPV) and ritonavir (RTV). Clinical trials (e.g., ChiCTR2000029539) are"/>
 <result pre="effective towards SARS-CoV and MERS-CoV such as lopinavir (LPV) and" exact="ritonavir" post="(RTV). Clinical trials (e.g., ChiCTR2000029539) are conducted to test"/>
 <result pre="5.1.2.2 Remdesivir Remdesivir (RDV) is a broad-spectrum anti-viral and an" exact="adenosine" post="triphosphate nucleoside analog. It is an investigational small molecule"/>
 <result pre="of RDV in hospitalized adults diagnosed with COVID-19 [85]. 5.1.2.3" exact="Ribavirin" post="Ribavirin (RBV) is an antiviral purine nucleoside analog approved"/>
 <result pre="RDV in hospitalized adults diagnosed with COVID-19 [85]. 5.1.2.3 Ribavirin" exact="Ribavirin" post="(RBV) is an antiviral purine nucleoside analog approved for"/>
 <result pre="respiratory syncytial virus (MERS-CoV, SARS-CoV-2) [86]. RBV is metabolized by" exact="adenosine" post="kinase to its prodrug mono, di and triphosphate metabolites."/>
 <result pre="it's given in combination with other antiviral drugs like lopinavir," exact="chloroquine" post="analogs and with interferon-Î± [90]. A Study on Vero"/>
 <result pre="bioavailability of 64%. It is metabolized in the liver by" exact="adenosine" post="kinase to its mono, di and tri phosphate metabolites."/>
 <result pre="the mortality in patients with COVID-19 infection compared with lopinavir/" exact="ritonavir" post="[94]. 5.1.2.4 Arbidol Arbidol (ARB) or Umifenovir is an"/>
 <result pre="randomized, open study to assess the safety and efficacy of" exact="Bromhexine" post="Hydrochloride tablets given in combination with ARB and recombinant"/>
 <result pre="DRV is used in trial number NCT04252274 in combination with" exact="cobicistat" post="[112]. Such a combination is currently approved by the"/>
 <result pre="in treating AIDS. DRV is a HIV protease inhibitor, and" exact="cobicistat" post="is a supplement to enhance DRV's pharmacodynamics and pharmacokinetics"/>
 <result pre="China [116]. Oseltamivir is also used in clinical trials with" exact="chloroquine" post="and FPV in multiple combinations [117]. 5.1.2.8 Interferons Interferons"/>
 <result pre="the in vitro studies of INF given in combination with" exact="ribavirin" post="showed a potent synergistic effect in treating SARS [122]."/>
 <result pre="effect in treating SARS [122]. The combination of INF and" exact="ribavirin" post="at a lower dose showed an inhibitory action on"/>
 <result pre="cells of lungs and results in the secretion of anti-inflammatory" exact="adenosine" post="[125]. These studies showed that INF can be used"/>
 <result pre="open-label controlled trial on the combination therapy of lopinavir/ ritonavir," exact="ribavirin" post="and INFÎ²1b in comparison with monotherapy of lopinavir/ ritonavir"/>
 <result pre="ritonavir, ribavirin and INFÎ²1b in comparison with monotherapy of lopinavir/" exact="ritonavir" post="as a treatment for novel coronavirus infection has been"/>
 <result pre="with COVID-19 infection have been initiated [127,128]. 5.1.3 Antibiotic 5.1.3.1" exact="Azithromycin" post="Azithromycin (AZ) is a semi synthetic broad spectrum macrolide"/>
 <result pre="COVID-19 infection have been initiated [127,128]. 5.1.3 Antibiotic 5.1.3.1 Azithromycin" exact="Azithromycin" post="(AZ) is a semi synthetic broad spectrum macrolide antibiotic"/>
 <result pre="[129]. There are several reports suggesting that a combination of" exact="chloroquine" post="and AZ is effective in reducing the viral load"/>
 <result pre="treatment of COVID-19. Usually a dose of 1â€&quot;2Â g of" exact="azithromycin" post="in combination with hydroxychloroquine or chloroquine is used in"/>
 <result pre="a dose of 1â€&quot;2Â g of azithromycin in combination with" exact="hydroxychloroquine" post="or chloroquine is used in the treatment of COVID-19."/>
 <result pre="of 1â€&quot;2Â g of azithromycin in combination with hydroxychloroquine or" exact="chloroquine" post="is used in the treatment of COVID-19. There are"/>
 <result pre="been initiated to compare the efficiency of the two drugs" exact="hydroxychloroquine" post="and AZ to see which one is better in"/>
 <result pre="the safety and efficacy of tocilizumab given in combination with" exact="azithromycin" post="and hydroxychloroquine in the treatment of SARS-CoV-2 [135]. A"/>
 <result pre="and efficacy of tocilizumab given in combination with azithromycin and" exact="hydroxychloroquine" post="in the treatment of SARS-CoV-2 [135]. A phase II"/>
 <result pre="has been initiated to evaluate the safety and effectiveness of" exact="hydroxychloroquine" post="and AZ to prevent the hospitalization or death in"/>
 <result pre="yrs age to deduce the efficacy of combination therapy of" exact="hydroxychloroquine" post="and AZ [137]. They concluded that hydroxychloroquine (500Â mg/day)"/>
 <result pre="combination therapy of hydroxychloroquine and AZ [137]. They concluded that" exact="hydroxychloroquine" post="(500Â mg/day) and AZ (250Â mg/ day for 5Â"/>
 <result pre="5Â days) successfully reduced the viral load. The activity of" exact="hydroxychloroquine" post="in reducing the viral load was further reinforced by"/>
 <result pre="reducing the viral load was further reinforced by AZ. 5.1.3.2" exact="Tetracycline" post="Tetracyclines (doxycycline, tetracyclines, minocycline) are a class of polyketide"/>
 <result pre="bacteriostatic activity against various bacterial infections. The bactericidal activity of" exact="tetracycline" post="is mainly due to its ability to reversibly bind"/>
 <result pre="potential antiviral activity against a host of virus including SARS-CoV-2." exact="Tetracycline" post="act by three possible mechanism against SARS-Cov-2 virus. Coronavirus"/>
 <result pre="the respiratory submucosa mast cells. The third possible mechanism of" exact="tetracycline" post="in treating COVID-19 is by inhibiting the replication of"/>
 <result pre="penetrating ability and lipophilic nature of tetracycline. The bioavailability of" exact="tetracycline" post="upon intramuscular injection is 40% and the oral bioavailability"/>
 <result pre="aim of this study is to assess the efficacy of" exact="doxycycline" post="in reducing/ abolishing the cytokine storm which is induced"/>
 <result pre="agent to prevent organ transplant rejection. The immunosuppressive activity of" exact="sirolimus" post="is mainly due to its ability to inhibit T-lymphocyte"/>
 <result pre="form a immunosuppressive complex and inhibits the mammalian target of" exact="rapamycin" post="(mTOR) kinase which in turn halts the formation of"/>
 <result pre="play an important role in viral replication. Studies showed that" exact="sirolimus" post="successfully inhibited mTOR signalling pathway and there by inhibited"/>
 <result pre="signalling pathway and there by inhibited MERS-CoV [150], thus making" exact="sirolimus" post="a suitable candidate to further test and use in"/>
 <result pre="blind, randomized, placebo controlled clinical trial on the use of" exact="sirolimus" post="in treating COVD-19. The aim of the study is"/>
 <result pre="aim of the study is to determine the efficacy of" exact="sirolimus" post="in improving the clinical outcomes among the patients hospitalized"/>
 <result pre="evaluate the pharmacokinetics, pharmacodynamics, virological efficacy, tolerability and safety of" exact="sirolimus" post="as an adjuvant therapy in treating patients with COVID-19"/>
 <result pre="investigate the safety and efficacy of combination therapy of lopinavir/ritonavir," exact="hydroxychloroquine" post="sulphate and baricitinib in the treatment of moderate to"/>
 <result pre="and investigate their efficacy in treating COVID-19. A combination of" exact="hydroxychloroquine" post="(200Â mg), ritonavir (50Â mg), baricitinib (4Â mg) and"/>
 <result pre="efficacy in treating COVID-19. A combination of hydroxychloroquine (200Â mg)," exact="ritonavir" post="(50Â mg), baricitinib (4Â mg) and imatinib (400Â mg)"/>
 <result pre="hydroxychloroquine (200Â mg), ritonavir (50Â mg), baricitinib (4Â mg) and" exact="imatinib" post="(400Â mg) will be administered to the patients with"/>
 <result pre="reducing the inflammatory responses [158]. In the case of COVID-19," exact="cyclosporine" post="blocks RNA-dependent-RNA polymerase and peptidyl-prolyl isomerase activity of SARS-CoV-2"/>
 <result pre="the angiotensin converting enzyme-2 (ACE-2) at a low cytosolic Ph," exact="cyclosporine" post="s known to maintain the cytosolic pH at normal"/>
 <result pre="in SARS-CoV-2 infection is mainly caused due to SHL and" exact="cyclosporine" post="is the choice of drug to treat SHL as"/>
 <result pre="cyclosporine is the choice of drug to treat SHL as" exact="cyclosporine" post="blocks the production of IL-2 and inhibits the proliferation"/>
 <result pre="a volume of distribution 0f 4â€&quot;8Â L/kg. The half-life of" exact="cyclosporine" post="is 19Â h and its metabolized in intestine and"/>
 <result pre="pre-clinical and clinical data proving the safety and efficacy of" exact="cyclosporine" post="in the treatment of COVID-19 available. 5.1.5 Monoclonal antibodies"/>
 <result pre="evaluate the use of TCZ when given in combination with" exact="azithromycin" post="and hydroxychloroquine in treating the patients hospitalized with COVID-19"/>
 <result pre="use of TCZ when given in combination with azithromycin and" exact="hydroxychloroquine" post="in treating the patients hospitalized with COVID-19 [135]. A"/>
 <result pre="paralysis and death of the parasite. The anti-viral activity of" exact="ivermectin" post="was first discovered with its ability to block the"/>
 <result pre="flavivirus and dengue virus [169]. The in vitro study of" exact="ivermectin" post="anti-viral activity against SARS-CoV-2 virus showed an inhibition of"/>
 <result pre="the safety and efficacy profile of the combination therapy of" exact="hydroxychloroquine" post="and ivermectin I the treatment of hospitalized COVD-19 patients"/>
 <result pre="and efficacy profile of the combination therapy of hydroxychloroquine and" exact="ivermectin" post="I the treatment of hospitalized COVD-19 patients [171]. 5.1.7"/>
 <result pre="(41.8%) patients acquired ARDS and 44 (52.4%) of those died." exact="Methylprednisolone" post="therapy reduced the risk of mortality in ARDS patients"/>
 <result pre="is planned to examine clinical progress in patients administered with" exact="methylprednisolone" post="IV [66,179]. In another study, Zhou et al. indicated"/>
 <result pre="emphasizes on the four most assuring therapies: the antimalarial medications" exact="chloroquine" post="and hydroxychloroquine, an antiviral compound remdesivir, a combination of"/>
 <result pre="messenger, interferon-beta that can aid in paralyzing the virus [191]." exact="Chloroquine" post="and hydroxychloroquine prevent the entry and transport of the"/>
 <result pre="that can aid in paralyzing the virus [191]. Chloroquine and" exact="hydroxychloroquine" post="prevent the entry and transport of the virus by"/>
 <result pre="the RNA synthesis leading to the induction of mutagenesis. Both" exact="ritonavir" post="and lopinavir being protease inhibitors block the viral cellular"/>
 <result pre="synthesis leading to the induction of mutagenesis. Both ritonavir and" exact="lopinavir" post="being protease inhibitors block the viral cellular entry where"/>
 <result pre="lopinavir being protease inhibitors block the viral cellular entry where" exact="ritonavir" post="inhibits Cyt-P450 and prolongs the half-life of lopinavir. Interferon-beta"/>
 <result pre="administration Category and purpose in COVID-19 Sponsor ClinicalTrials.gov identifier 1" exact="Chloroquine" post="2 &amp;amp; 3, 4, 2 Oral route Antimalarial, to"/>
 <result pre="Oxford University Clinical Research Unit, Vietnam NCT04333628, NCT04331600, NCT04328493 2" exact="Hydroxychloroquine" post="3, 3, 2, 2, 2 Oral route Antimalarial, to"/>
 <result pre="Antiviral in treatment of COVID-19 Gilead Sciences, NCT04292899, NCT04292730 4" exact="Azithromycin" post="3 Oral route Antibiotic, to prevent COVD-19 disease progression"/>
 <result pre="patients Sunnybrook Health Sciences Centre, Canada NCT04330690 7 Lopinavir/ritonavir vs" exact="Hydroxychloroquine" post="sulfate 2 Oral route To treat Mild COVID-19 Asan"/>
 <result pre="Lisa Barrett, Canada NCT04321993 9 Remdesivir, Lopinavir/ritonavir, interferon Î²-1A, and" exact="hydroxychloroquine" post="3 I.V infusion, oral route, S.C injection, and oral"/>
 <result pre="of Health and Medical Research, France NCT04315948 10 Hydroxychloroquine, Oseltamivir," exact="Azithromycin" post="3 Oral route To treat COVID-19 patients Shehnoor Azhar,"/>
 <result pre="route To treat COVID-19 patients Shehnoor Azhar, Pakistan NCT04338698 11" exact="Hydroxychloroquine" post="and Nitazoxanide 2, 3 Oral route To evaluate safety"/>
 <result pre="safety and efficacy in COVID-19 patients Tanta University NCT04361318 12" exact="Hydroxychloroquine" post="vs. Azithromycin 2, 3 Oral route To treat COVID-19"/>
 <result pre="efficacy in COVID-19 patients Tanta University NCT04361318 12 Hydroxychloroquine vs." exact="Azithromycin" post="2, 3 Oral route To treat COVID-19 patients Intermountain"/>
 <result pre="Intermountain Medical Center, United States NCT04329832, NCT04334382 13 1. Lopinavir/ritonavir,2." exact="Ribavirin" post="and3. Interferon beta-1b 2 1 &amp;amp; 2 oral route,"/>
 <result pre="Second Affiliated Hospital of Wenzhou Medical University, China NCT04273763 20" exact="Deferoxamine" post="1 &amp;amp; 2 Intravenous infusion Iron chelator, to reduce"/>
 <result pre="University Hospital, Spain NCT04325061 22 Piclidenoson 2 Oral route A3" exact="adenosine" post="receptor agonist, to treat COVID-19 patients Can-Fite BioPharma, Israel"/>
 <result pre="route Adjuvant treatment of COVID-19 Tongji Hospital, China NCT04291053 25" exact="Tranexamic acid" post="2 Oral route Antifibrinolytics, to study its effect on"/>
 <result pre="COVID-19 University of Kansas Medical Center, United States NCT04335123 29" exact="Telmisartan" post="2 Oral route Angiotensin receptor blocker, to evaluate the"/>
 <result pre="the deteroration of COVID-19 patients Mount Auburn Hospital NCT04380402 31" exact="Prazosin" post="2 Oral route Alpha-blockers, to evaluate the safety and"/>
 <result pre="for COVID-19 treatment Centre Hospitalier St Anne, France NCT04366739 33" exact="Lenalidomide" post="4 Oral route Antiangiogenic agent, to treat mild to"/>
 <result pre="C5a antibody, to treat pneumonia. InflaRx GmbH, Netherlands NCT04333420 42" exact="Acalabrutinib" post="with Best supportive care 2 Oral route Bruton's tyrosine"/>
 <result pre="with cytokine release syndrome Novartis Pharmaceuticals, United States NCT04362813 46" exact="Ruxolitinib" post="2 â€&quot; Kinase inhibitor, to treat hyper inflammation in"/>
 <result pre="with stage II/III COVID-19 Dr. Andreas Hochhaus, Germany NCT04338958 47" exact="Ruxolitinib" post="3 Oral route To evaluate safety and efficacy in"/>
 <result pre="vitro for an antiviral and antimalarial drug namely remdesivir and" exact="chloroquine" post="have shown promising results in suppressing the virus. In"/>
 <result pre="into the antiviral effects of chloroquineLancet Infect. Dis.62006676910.1016/S1473-3099(06)70361-916439323 63YanY.ZouZ.SunY.LiX.XuK.-F.WeiY.JinN.JiangC.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
 <result pre="inhibitor of SARS coronavirus infection and spreadVirol. J.220056910.1186/1743-422X-2-6916115318 65WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="organization registered platform, (n.d.). http://www.chictr.org.cn/showprojen.aspx?proj=49145 (accessed April 8, 2020). 67GaoJ.TianZ.YangX.Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
 <result pre="Med. Chem.4920062845284910.1021/jm060185616640347 69MarmorM.F.KellnerU.LaiT.Y.Y.MellesR.B.MielerW.F.American academy of ophthalmology, recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 revision)Ophthalmology.12320161386139410.1016/j.ophtha.2016.01.05826992838 70D. Zhou, S.-M. Dai,"/>
 <result pre="69MarmorM.F.KellnerU.LaiT.Y.Y.MellesR.B.MielerW.F.American academy of ophthalmology, recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 revision)Ophthalmology.12320161386139410.1016/j.ophtha.2016.01.05826992838 70D. Zhou, S.-M. Dai, Q. Tong,"/>
 <result pre="Q. Tong, COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progression, J. Antimicrob. Chemother.. (n.d.)."/>
 <result pre="infection and progression, J. Antimicrob. Chemother.. (n.d.). doi:10.1093/jac/dkaa114. 71GautretP.LagierJ.C.ParolaP.HoangV.T.MeddedL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonoreS.ColsonP.ChabriereE.ScolaB.L.RolainJ.M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="Azithromycin" post="as a Treatment of COVID-19: Preliminary Results of an"/>
 <result pre="clinically approved antiviral drugsEmerg. Infect. Dis.10200458158610.3201/eid1004.03045815200845 87TeH.S.RandallG.JensenD.M.Mechanism of action of" exact="ribavirin" post="in the treatment of chronic hepatitis CGastroenterol Hepatol (N"/>
 <result pre="chronic hepatitis CGastroenterol Hepatol (N Y)3200721822521960835 88GraciJ.D.CameronC.E.Mechanisms of action of" exact="ribavirin" post="against distinct virusesRev. Med. Virol.162006374810.1002/rmv.48316287208 89Ã–lschlÃ¤gerS.NeytsJ.GÃ¼ntherS.Depletion of GTP pool"/>
 <result pre="of GTP pool is not the predominant mechanism by which" exact="ribavirin" post="exerts its antiviral effect on Lassa virusAntivir. Res.912011899310.1016/j.antiviral.2011.05.00621616094 90FalzaranoD.de"/>
 <result pre="&amp;amp; Therapeutics142020586010.5582/ddt.2020.0101232147628 92KnowlesS.R.PhillipsE.J.DresserL.MatukasL.Common adverse events associated with the use of" exact="ribavirin" post="for severe acute respiratory syndrome in CanadaClin. Infect. Dis.3720031139114210.1086/37830414523782"/>
 <result pre="the treatment of SARS: initial virological and clinical findingsThorax59200425225610.1136/thorax.2003.01265814985565 94Lopinavir/Ritonavir," exact="Ribavirin" post="and IFN-beta combination for nCoV treatment - full text"/>
 <result pre="(accessed April 9, 2020). 106Evaluating the efficacy and safety of" exact="bromhexine" post="hydrochloride tablets combined with standard treatment/standard treatment in patients"/>
 <result pre="(accessed May 17, 2020). 112LuH.Efficacy and safety of darunavir and" exact="cobicistat" post="for treatment of COVID-19, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT042522742020 113SantosJ.R.CurranA.Navarro-MercadeJ.AmpueroM.F.PelaezP.PÃ©rez-AlvarezN.ClotetB.ParedesR.MoltÃ³J.Simplification of antiretroviral treatment"/>
 <result pre="prospective, open label, randomized, in Multicenter Study of, Oseltamivir Plus" exact="Hydroxychloroquine" post="Versus Lopipinavir/Ritonavir Plus Oseltamivir Versus Darunavir/Ritonavir Plus Oseltamivir Plus"/>
 <result pre="Hydroxychloroquine Versus Lopipinavir/Ritonavir Plus Oseltamivir Versus Darunavir/Ritonavir Plus Oseltamivir Plus" exact="Hydroxychloroquine" post="in Mild COVID-19 AND Lopipinavir/Ritonavir Plus Oseltamivir Versus Favipiravir"/>
 <result pre="Oseltamivir Versus Favipiravir Plus Lopipinavir/Ritonavir Versus Darunavir/Ritonavir Plus Oseltamivir Plus" exact="Hydroxychloroquine" post="Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in"/>
 <result pre="Darunavir/Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and" exact="Ritonavir" post="Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043032992020"/>
 <result pre="Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus" exact="Hydroxychloroquine" post="in Moderate to Critically Ill COVID-19, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043032992020 118LiuY.-J.IPC: professional"/>
 <result pre="Chemother.63201910.1128/AAC.00394-19e00394-19, /aac/63/12/AAC.00394-19.atom 133DamleB.VourvahisM.WangE.LeaneyJ.CorriganB.Clinical pharmacology perspectives on the antiviral activity of" exact="azithromycin" post="and use in COVID-19Clin. Pharmacol. Ther.202010.1002/cpt.1857(cpt.1857) 134Hydroxychloroquine vs. azithromycin"/>
 <result pre="of azithromycin and use in COVID-19Clin. Pharmacol. Ther.202010.1002/cpt.1857(cpt.1857) 134Hydroxychloroquine vs." exact="azithromycin" post="for hospitalized patients with suspected or confirmed COVID-19 -"/>
 <result pre="(n.d.). https://clinicaltrials.gov/ct2/show/NCT04332094 (accessed May 18, 2020). 136Evaluating the efficacy of" exact="hydroxychloroquine" post="and azithromycin to prevent hospitalization or death in persons"/>
 <result pre="(accessed May 18, 2020). 136Evaluating the efficacy of hydroxychloroquine and" exact="azithromycin" post="to prevent hospitalization or death in persons with COVID-19"/>
 <result pre="ClinicalTrials.gov, (n.d.). https://clinicaltrials.gov/ct2/show/NCT04358068 (accessed May 18, 2020). 137GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonorÃ©S.ColsonP.ChabriÃ¨reE.La ScolaB.RolainJ.-M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="evaluating the virological efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of" exact="sirolimus" post="adjuvant therapy in patients with coronavirus disease (COVID-19), clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043716402020"/>
 <result pre="ClinicalTrials.gov, (n.d.). https://clinicaltrials.gov/ct2/show/NCT04346147 (accessed May 19, 2020). 157ChighizolaC.B.OngV.H.MeroniP.L.The use of" exact="cyclosporine" post="a in rheumatology: a 2016 comprehensive reviewClinic Rev Allerg"/>
 <result pre="inhibits the replication of diverse coronavirusesJ. Gen. Virol.9220112542254810.1099/vir.0.034983-021752960 160CureE.Cumhur CureM.Can" exact="dapagliflozin" post="have a protective effect against COVID-19 infection? A hypothesisDiabetes"/>
 <result pre="of HIV-1 and dengue virusBiochem. J.443201285185610.1042/BJ2012015022417684 169YangS.N.Y.AtkinsonS.C.WangC.LeeA.BogoyevitchM.A.BorgN.A.JansD.A.The broad spectrum antiviral" exact="ivermectin" post="targets the host nuclear transport importin Î±/Î²1 heterodimerAntivir. Res.177202010476010.1016/j.antiviral.2020.104760"/>
 <result pre="host nuclear transport importin Î±/Î²1 heterodimerAntivir. Res.177202010476010.1016/j.antiviral.2020.104760 170CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir. Res.178202010478710.1016/j.antiviral.2020.104787 171Centenario"/>
 <result pre="in vitroAntivir. Res.178202010478710.1016/j.antiviral.2020.104787 171Centenario Hospital Miguel HidalgoEfficacy and safety of" exact="hydroxychloroquine" post="and ivermectin in hospitalized no critical patients secondary to"/>
 <result pre="Res.178202010478710.1016/j.antiviral.2020.104787 171Centenario Hospital Miguel HidalgoEfficacy and safety of hydroxychloroquine and" exact="ivermectin" post="in hospitalized no critical patients secondary to COVID-19 infection:"/>
 <result pre="megatrial of the four most promising coronavirus treatmentsScience222020 192SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
 <result pre="197covexit, Professor Didier Raoult releases the results of a New" exact="Hydroxychloroquine" post="Treatment Study on 1061 patients â€&quot; COVEXIT.com, (n.d.). http://covexit.com/professor-didier-raoult-releases-the-results-of-a-new-hydroxychloroquine-treatment-study-on-1061-patients/"/>
</results>
